Cerecin and IMCB signed a Memorandum of Understanding to collaborate in the areas of neurometabolism, neurodegeneration, metabolic regulators, and brain health and function.SINGAPORE and DENVER, Nov. 30, 2023 /PRNewswire/ -- Cerecin Inc., a clinical-stage biotechnology company at the forefront of developing innovative neurotherapeutics, is pleased to announce the establishment of a Memorandum of Understanding (MOU) with A*STAR's Institute of Molecular and Cell Biology (IMCB).

Cerecin和IMCB签署了一份谅解备忘录，在神经代谢，神经退行性疾病，代谢调节因子以及大脑健康和功能方面开展合作。新加坡和丹佛，2023年11月30日/PRNewswire/-Cerecin Inc.，一家处于开发创新神经治疗药物前沿的临床阶段生物技术公司，很高兴宣布与*STAR's建立谅解备忘录（MOU）。分子与细胞生物学研究所（IMCB）。

This collaboration aims to accelerate research and treatment initiatives for neurological disorders and diseases to enhance overall health and brain function..

这项合作旨在加快神经系统疾病和疾病的研究和治疗举措，以增强整体健康和大脑功能。。

Continue Reading

继续阅读

Cerecin and A*Star Sign MOU

Cerecin和*明星签名MOU

Worldwide, there are about two billion cases of neurological and mental health diseases. Unlike other therapeutic areas, 80% of these patients are completely unserved or have been inadequately served by current medicines with which to treat their conditions. This makes brain health one of the medical fields with the highest unmet need.

全世界约有20亿例神经和精神疾病。与其他治疗领域不同，这些患者中有80%完全没有服务，或者目前用于治疗其疾病的药物服务不足。这使得大脑健康成为未满足需求最高的医疗领域之一。

In Singapore alone, more than one in four will suffer from a neurological condition within their lifetime..

仅在新加坡，一生中将有四分之一以上的人患有神经系统疾病。。

It is becoming increasingly clear that neurometabolic dysfunction is a driver of many neurological and neurodegenerative diseases, and that metabolic and brain health are closely intertwined. Hence, in their collaboration, A*STAR's IMCB will combine preclinical modelling tools with multi-omics approaches to analyse bio samples in neurological diseases (such as Alzheimer's disease) from Cerecin's clinical cohorts.

越来越清楚的是，神经代谢功能障碍是许多神经和神经退行性疾病的驱动因素，代谢和大脑健康密切相关。因此，在他们的合作中，A*STAR的IMCB将结合临床前建模工具和多组学方法来分析来自Cerecin临床队列的神经系统疾病（如阿尔茨海默病）中的生物样本。

The goal is to understand the fundamental causes of these neurological diseases, especially their metabolic origins, to identify new treatment targets and disease indicators, and to develop innovative treatment approaches.  .

目标是了解这些神经系统疾病的根本原因，特别是其代谢起源，确定新的治疗目标和疾病指标，并开发创新的治疗方法。 .

'We are very pleased to embark on this collaborative journey with A*STAR's IMCB, focused initially on working with its Neurometabolism division' said Dr Charles Stacey, CEO and President of Cerecin. 'This partnership represents a further step in our commitment to driving advances in neurometabolism and underscores our dedication to providing cutting-edge solutions.

“我们非常高兴地与A*STAR的IMCB开展这项合作之旅，最初专注于与其神经代谢部门的合作。”Cerecin首席执行官兼总裁Charles Stacey博士说这种伙伴关系代表了我们致力于推动神经代谢进步的进一步一步，并强调了我们致力于提供尖端解决方案。

Singapore has a rapidly ageing population. As age is the leading risk factor for many neurodegenerative diseases, we are proud to form one of the first public-private collaborations in brain health.'Dr Su Xinyi, Acting Executive Director at A*STAR's IMCB said, 'Public-private partnerships are key enablers in translating science into impact.

新加坡人口迅速老龄化。由于年龄是许多神经退行性疾病的主要危险因素，因此我们很自豪地成为大脑健康领域的首批公私合作之一A*STAR IMCB代理执行董事苏新毅博士表示，“公私合作伙伴关系是将科学转化为影响力的关键推动因素。

IMCB's expertise in neurometabolism, cell biology, transformational biotherapeutics and diagnostics, coupled with Cerecin's expertise, will help pave the way for innovative developments in neurotherapeutics and contribute to better health outcomes for Singapore and beyond.'About Cerecin: Cerecin is a clinical-stage biotechnology company focused on developing drugs that target the metabolic bases of central nervous system diseases.

IMCB在神经代谢，细胞生物学，转化生物治疗学和诊断学方面的专业知识，加上Cerecin的专业知识，将有助于为神经治疗学的创新发展铺平道路，并为新加坡及其他地区的健康结果做出贡献关于Cerecin:Cerecin是一家临床阶段的生物技术公司，专注于开发针对中枢神经系统疾病代谢基础的药物。

Cerecin is supported by two multinational partners, Nestlé S.A. (NSRGY) and Wilmar International Limited (SGX: F34), as well as a syndicate of leading institutional investors. By bringing together the deep expertise of its leadership team, Cerecin is becoming a global leader in bioenergetics and neurometabolism.Forward looking statements:This press release contains 'forward-looking statements' under applicable securities laws that are based on the current expectations and beliefs of Cerecin.

Cerecin得到了两家跨国合作伙伴雀巢（NSRGY）和Wilmar International Limited（SGX:F34）以及领先机构投资者集团的支持。通过汇集其领导团队的深刻专业知识，Cerecin正在成为生物能量学和神经代谢领域的全球领导者。前瞻性声明：本新闻稿包含适用证券法下的“前瞻性声明”，这些声明基于Cerecin的当前期望和信念。

Such statements may be accompanied by words such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'intend,' 'may,' 'plan,' 'pote.

这样的陈述可能伴随着诸如“目标”，“预期”，“相信”，“可以”，“估计”，“期望”，“预测”，“意图”，“可能”，“计划”，“潜力”之类的词语。